Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Five-period, Balanced Crossover Study to Evaluate the Relative Bioavailability of an Eltrombopag Powder for Oral Suspension (PfOS) Formulation Relative to the Commercial 25 mg Tablet Formulation and to Evaluate Administration of the PfOS Formulation With and Separated 2 Hours From a High Calcium Meal in Healthy Adult Subjects
Conditions
Interventions
Eltrombopag
Eltrombopag
Locations
1
United States
GSK Investigational Site
Buffalo, New York, United States
Start Date
January 12, 2010
Primary Completion Date
April 7, 2010
Completion Date
April 7, 2010
Last Updated
November 14, 2017
NCT00442871
NCT01064336
NCT01098487
NCT00424177
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions